title: Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
abstract: Tiazofurin (2-B-D-Ribofuranosylthiazole-4-Carboxamide: NSC 286193) is a nucleoside antimetabolite that acts as a potent inhibitor of IMP dehydrogenase resulting in a guanine nucleotide deprivation. Recent in vivo biochemical observations in rats bearing hepatoma suggested a correlation between depletion of guanine nucleotides and antitumor effect. The present phase I trial utilized a weekly x 3 bolus infusion schedule, repeated every 5 weeks. Biochemical measurements of GTP and dGTP were performed in patients at each dose level. Twelve patients received 16 courses of the drug in doses ranging from 1100 to 2050 mg/m2 weekly x 3. The dose limiting toxicities were pericarditis and clinical symptoms suggestive of a more generalized serositis (chest and abdominal pain). Other toxicities included reversible elevations in CPK (MM band only) and SGOT, nausea, vomiting, and arthralgias. Neurotoxic effects were generally mild, including headaches, anxiety, and malaise. Only 1 of 6 patients evaluated for tiazofurin's biochemical activity showed a sustained depletion of guanine nucleotide pools. No antitumor activity was observed. The maximally tolerated dose of tiazofurin on this intermittent weekly x 3 schedule was 1650 mg/m2. Toxicity and the overall lack of biochemical and biologic effect at clinically achievable doses may preclude further clinical evaluation of this drug on a weekly schedule. The toxicities observed in our study were similar to those reported for phase I investigations using a considerably higher dose intensity with daily x 5 schedules.
authors.affiliation: Department of Medicine, University of Texas Health Science Center, San Antonio.
authors.forename: T J
authors.initials: TJ
authors.lastname: Melink
authors.forename: G
authors.initials: G
authors.lastname: Sarosy
authors.forename: A R
authors.initials: AR
authors.lastname: Hanauske
authors.forename: J L
authors.initials: JL
authors.lastname: Phillips
authors.forename: J H
authors.initials: JH
authors.lastname: Bayne
authors.forename: M R
authors.initials: MR
authors.lastname: Grever
authors.forename: H N
authors.initials: HN
authors.lastname: Jayaram
authors.forename: D D
authors.initials: DD
authors.lastname: Von Hoff
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D012263:Ribonucleosides; D012254:Ribavirin; C033706:tiazofurin